JP2020534250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534250A5 JP2020534250A5 JP2020503721A JP2020503721A JP2020534250A5 JP 2020534250 A5 JP2020534250 A5 JP 2020534250A5 JP 2020503721 A JP2020503721 A JP 2020503721A JP 2020503721 A JP2020503721 A JP 2020503721A JP 2020534250 A5 JP2020534250 A5 JP 2020534250A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- conjugate
- antigen
- pharmaceutical composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 60
- 229940127121 immunoconjugate Drugs 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 51
- 108091007433 antigens Proteins 0.000 claims description 51
- 239000012634 fragment Substances 0.000 claims description 51
- 238000002560 therapeutic procedure Methods 0.000 claims description 48
- 230000000259 anti-tumor effect Effects 0.000 claims description 44
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 32
- 239000000562 conjugate Substances 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000003384 imaging method Methods 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 11
- 108091006088 activator proteins Proteins 0.000 claims description 8
- 239000000611 antibody drug conjugate Substances 0.000 claims description 8
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 8
- 239000007850 fluorescent dye Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 230000004807 localization Effects 0.000 claims description 6
- -1 radiotherapy Proteins 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 238000012879 PET imaging Methods 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000002600 positron emission tomography Methods 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 230000009260 cross reactivity Effects 0.000 claims description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101710112752 Cytotoxin Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 229940125555 TIGIT inhibitor Drugs 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000003127 anti-melanomic effect Effects 0.000 claims description 2
- 230000001826 anti-prostatic effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000958 deferoxamine Drugs 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 238000012632 fluorescent imaging Methods 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 229960003876 ranibizumab Drugs 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- 210000001072 colon Anatomy 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
- PILNWOQIOBWPRE-UHFFFAOYSA-O CCCCCN(/C(/C1(C)C)=C/C=C(\CCC2)/C(Oc(cc3)ccc3S(O)(=O)=O)=C2/C=C/C(C2(C)C)=[N+](CCCCCC(C)=O)c(cc3)c2cc3S(O)(=O)=O)c(cc2)c1cc2S(O)(=O)=O Chemical compound CCCCCN(/C(/C1(C)C)=C/C=C(\CCC2)/C(Oc(cc3)ccc3S(O)(=O)=O)=C2/C=C/C(C2(C)C)=[N+](CCCCCC(C)=O)c(cc3)c2cc3S(O)(=O)=O)c(cc2)c1cc2S(O)(=O)=O PILNWOQIOBWPRE-UHFFFAOYSA-O 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000031844 Squamous cell carcinoma of the rectum Diseases 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000012977 squamous cell carcinoma of rectum Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023104924A JP7746334B2 (ja) | 2017-07-24 | 2023-06-27 | 抗ｃｄ８抗体およびその使用 |
| JP2025154255A JP2026009919A (ja) | 2017-07-24 | 2025-09-17 | 抗ｃｄ８抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536239P | 2017-07-24 | 2017-07-24 | |
| US62/536,239 | 2017-07-24 | ||
| US201862660902P | 2018-04-20 | 2018-04-20 | |
| US62/660,902 | 2018-04-20 | ||
| PCT/US2018/043343 WO2019023148A1 (en) | 2017-07-24 | 2018-07-23 | ANTI-CD8 ANTIBODIES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023104924A Division JP7746334B2 (ja) | 2017-07-24 | 2023-06-27 | 抗ｃｄ８抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534250A JP2020534250A (ja) | 2020-11-26 |
| JP2020534250A5 true JP2020534250A5 (https=) | 2021-09-02 |
| JP7304846B2 JP7304846B2 (ja) | 2023-07-07 |
Family
ID=63143411
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503721A Active JP7304846B2 (ja) | 2017-07-24 | 2018-07-23 | 抗ｃｄ８抗体およびその使用 |
| JP2023104924A Active JP7746334B2 (ja) | 2017-07-24 | 2023-06-27 | 抗ｃｄ８抗体およびその使用 |
| JP2025154255A Pending JP2026009919A (ja) | 2017-07-24 | 2025-09-17 | 抗ｃｄ８抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023104924A Active JP7746334B2 (ja) | 2017-07-24 | 2023-06-27 | 抗ｃｄ８抗体およびその使用 |
| JP2025154255A Pending JP2026009919A (ja) | 2017-07-24 | 2025-09-17 | 抗ｃｄ８抗体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10730944B2 (https=) |
| EP (1) | EP3658193A1 (https=) |
| JP (3) | JP7304846B2 (https=) |
| KR (2) | KR102880156B1 (https=) |
| CN (1) | CN110997013B (https=) |
| AU (2) | AU2018307744C1 (https=) |
| BR (1) | BR112020001360A2 (https=) |
| CA (1) | CA3070796A1 (https=) |
| CL (1) | CL2020000192A1 (https=) |
| CO (1) | CO2020000680A2 (https=) |
| IL (2) | IL316355A (https=) |
| MA (1) | MA49683A (https=) |
| MX (2) | MX2020000916A (https=) |
| MY (1) | MY197688A (https=) |
| PH (1) | PH12020550008A1 (https=) |
| SG (1) | SG11202000073XA (https=) |
| WO (1) | WO2019023148A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP3548515B1 (en) | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| KR102880156B1 (ko) | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| WO2021142231A1 (en) * | 2020-01-10 | 2021-07-15 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| CN111413298A (zh) * | 2020-05-27 | 2020-07-14 | 深圳市天安至远传感科技有限公司 | 一种光纤表面等离子体共振传感器、制备方法及检测系统 |
| US20240209089A1 (en) * | 2020-07-21 | 2024-06-27 | Suzhou Smartnuclide Biopharmaceutical Co., Ltd. | Cd8 binding polypeptide and use thereof |
| KR20230050389A (ko) | 2020-08-13 | 2023-04-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-2를 관심 표적 세포로 재지시하는 방법 |
| CN114112868B (zh) * | 2020-08-26 | 2024-12-13 | 上海睿昂基因科技股份有限公司 | 一种用于监测肿瘤相关免疫微环境的流式细胞术试剂盒及监测方法 |
| TW202231292A (zh) * | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 |
| EP4232071A4 (en) * | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| IL307544A (en) | 2021-04-08 | 2023-12-01 | Sana Biotechnology Inc | Cd8-specific antibody constructs and compositions thereof |
| AU2022275666A1 (en) | 2021-05-19 | 2023-12-07 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| WO2022248835A1 (en) * | 2021-05-26 | 2022-12-01 | Oxford Biotherapeutics Ltd | Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor |
| CN114230665B (zh) * | 2021-06-23 | 2024-03-22 | 苏州智核生物医药科技有限公司 | CD8α结合多肽及其用途 |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ抗体およびその使用 |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| EP4556493A1 (en) | 2022-07-11 | 2025-05-21 | Genuv Inc. | Cytokine fusion protein |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| CN115337413B (zh) * | 2022-08-08 | 2023-08-22 | 中国科学院近代物理研究所 | 一种针对非小细胞肺癌诊断的放射性分子探针的制备及应用 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| CN115746137A (zh) * | 2022-10-13 | 2023-03-07 | 华道(上海)生物医药有限公司 | 一种抗cd8抗体及其应用 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| CN120917051A (zh) | 2023-03-16 | 2025-11-07 | 天劢源和有限公司(开曼) | 多特异性抗原结合蛋白及其用途 |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN119684430A (zh) * | 2023-09-22 | 2025-03-25 | 深圳华大生命科学研究院 | 一种抗原多肽、由其制备的抗体及其在检测cd8中的应用 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025128807A1 (en) | 2023-12-13 | 2025-06-19 | Amgen Inc. | Radiolabeled compounds for the detection of steap1 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118745228B (zh) * | 2024-07-04 | 2025-09-23 | 杭州百凌生物科技有限公司 | 一种抗cd8抗体及其应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| US20080260650A1 (en) | 2004-10-28 | 2008-10-23 | The General Hospital Corporation | Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation |
| US20080193376A1 (en) | 2004-10-28 | 2008-08-14 | The General Hospital Corporation | Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation |
| US8889100B2 (en) | 2007-01-11 | 2014-11-18 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| WO2008124467A1 (en) | 2007-04-06 | 2008-10-16 | Macrocyclics | Bifunctional hydroxamic acid ligands and method of synthesis |
| CA2710149A1 (en) | 2007-12-21 | 2009-07-09 | John C. Anthes | C20-c21 substituted glucocorticoid receptor agonists |
| US20090297439A1 (en) | 2008-06-02 | 2009-12-03 | Metheresis Translational Research Sa, | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits |
| BRPI0915582A2 (pt) | 2008-06-06 | 2016-01-26 | Baylor Res Inst | anticorpos anto-cd8 que bloqueiam a sensibilização de efetores citotóxicos e levam à geração de células t cd8+ reguladoras |
| RU2613886C2 (ru) | 2010-06-03 | 2017-03-21 | Дженентек, Инк. | Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения |
| PE20141114A1 (es) | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| CA2860528A1 (en) | 2012-01-06 | 2013-07-11 | Linxis B.V. | Method for preparing cell targeting conjugates using functional metal ion constructs |
| WO2013138696A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| AU2013256596A1 (en) | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| BR112014028366A2 (pt) | 2012-05-21 | 2017-06-27 | Genentech Inc | anticorpos anti-ly6e e imunoconjugados e métodos de uso |
| US20150191543A1 (en) | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| US20150246146A1 (en) | 2012-10-25 | 2015-09-03 | Life Technologies Corporation | Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins |
| EP2740726A1 (en) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US9429584B2 (en) | 2013-02-28 | 2016-08-30 | National Cancer Center | Antibody against insoluble fibrin |
| CA2904969C (en) * | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| US20160000946A1 (en) | 2013-03-14 | 2016-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma |
| AU2014244424A1 (en) | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| US20170035917A1 (en) | 2013-06-10 | 2017-02-09 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| KR102313341B1 (ko) | 2013-08-26 | 2021-10-18 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산 |
| CN105658237B (zh) | 2013-10-21 | 2021-03-09 | 基因泰克公司 | 抗Ly6E抗体及使用方法 |
| HUE043875T2 (hu) | 2013-11-19 | 2019-09-30 | Fredax Ab | Humanizált, kallikrein-2 elleni antitest |
| EA201691214A1 (ru) | 2013-12-13 | 2016-12-30 | Дженентек, Инк. | Антитела к cd33 и иммуноконъюгаты |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| CN106794264B (zh) | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| BR112016028838A2 (pt) | 2014-06-11 | 2017-10-24 | Genentech Inc | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| US9546206B2 (en) | 2014-08-08 | 2017-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity PD-1 agents and methods of use |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| LT3191135T (lt) | 2014-09-12 | 2020-11-25 | Genentech, Inc. | Anti-her2 antikūnai ir imunokonjugatai |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| CN104360049B (zh) * | 2014-09-22 | 2016-08-17 | 重庆医科大学附属儿童医院 | 一种t淋巴细胞免疫分型的方法和试剂盒 |
| JP6689836B2 (ja) | 2014-10-16 | 2020-04-28 | ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ | 新規なイメージング組成物およびその使用 |
| ES2981335T3 (es) | 2014-11-25 | 2024-10-08 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| EP3265134B1 (en) | 2015-03-06 | 2021-12-15 | Mayo Foundation for Medical Education and Research | Methods for cell labeling and medical imaging |
| NL2014423B1 (en) | 2015-03-09 | 2016-10-13 | Linxis B V | Method for removing weakly bound functional moieties from cell targeting conjugates. |
| ES2941968T3 (es) | 2015-10-01 | 2023-05-29 | The Whitehead Institute For Biomedical Res | Marcaje de anticuerpos |
| EP3377117A1 (en) | 2015-11-18 | 2018-09-26 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| HUE054306T2 (hu) | 2016-05-19 | 2021-08-30 | Bristol Myers Squibb Co | Immunmodulátorok PET-képalkotás számára |
| WO2017213494A1 (en) | 2016-06-06 | 2017-12-14 | Linxis B.V. | Cell targeting conjugates |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| EP3266465A1 (en) | 2016-07-06 | 2018-01-10 | Julius-Maximilians-Universität Würzburg | Immune complexes |
| US11633506B2 (en) | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| EP3484513B1 (en) | 2016-07-18 | 2023-06-07 | Wisconsin Alumni Research Foundation | Radiohalogenated agents for combined cancer therapy |
| WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
| CN110191721A (zh) | 2016-09-26 | 2019-08-30 | 集合集团控股公司 | 有淋巴系统失调的受试者中癌症的评估与治疗方法 |
| WO2018128664A2 (en) | 2016-10-20 | 2018-07-12 | The University Of North Carolina At Chapel Hill | 18f-labeled compounds for pet imaging and uses thereof |
| US11266639B2 (en) | 2016-11-07 | 2022-03-08 | Vidac Pharma Ltd. | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers |
| KR102880156B1 (ko) | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
-
2018
- 2018-07-23 KR KR1020207004275A patent/KR102880156B1/ko active Active
- 2018-07-23 CN CN201880053140.1A patent/CN110997013B/zh active Active
- 2018-07-23 AU AU2018307744A patent/AU2018307744C1/en active Active
- 2018-07-23 MX MX2020000916A patent/MX2020000916A/es unknown
- 2018-07-23 JP JP2020503721A patent/JP7304846B2/ja active Active
- 2018-07-23 KR KR1020257036265A patent/KR20250162627A/ko active Pending
- 2018-07-23 CA CA3070796A patent/CA3070796A1/en active Pending
- 2018-07-23 MA MA049683A patent/MA49683A/fr unknown
- 2018-07-23 IL IL316355A patent/IL316355A/en unknown
- 2018-07-23 WO PCT/US2018/043343 patent/WO2019023148A1/en not_active Ceased
- 2018-07-23 SG SG11202000073XA patent/SG11202000073XA/en unknown
- 2018-07-23 BR BR112020001360-9A patent/BR112020001360A2/pt unknown
- 2018-07-23 US US16/043,048 patent/US10730944B2/en active Active
- 2018-07-23 IL IL271901A patent/IL271901B2/en unknown
- 2018-07-23 MY MYPI2020000164A patent/MY197688A/en unknown
- 2018-07-23 EP EP18752377.4A patent/EP3658193A1/en active Pending
-
2020
- 2020-01-07 PH PH12020550008A patent/PH12020550008A1/en unknown
- 2020-01-22 CO CONC2020/0000680A patent/CO2020000680A2/es unknown
- 2020-01-23 CL CL2020000192A patent/CL2020000192A1/es unknown
- 2020-01-23 MX MX2024014445A patent/MX2024014445A/es unknown
- 2020-06-26 US US16/914,112 patent/US11525001B2/en active Active
-
2022
- 2022-10-26 US US18/049,972 patent/US12077587B2/en active Active
-
2023
- 2023-06-27 JP JP2023104924A patent/JP7746334B2/ja active Active
-
2024
- 2024-07-23 US US18/781,469 patent/US20240409637A1/en active Pending
-
2025
- 2025-08-05 AU AU2025213570A patent/AU2025213570A1/en active Pending
- 2025-09-17 JP JP2025154255A patent/JP2026009919A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534250A5 (https=) | ||
| JP7624033B2 (ja) | Ｐｄ－１阻害剤を投与することによって皮膚がんを処置する方法 | |
| JP2020507571A5 (https=) | ||
| JP2020512281A5 (https=) | ||
| JP2022078265A (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| JP2020103301A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| JP2021531764A5 (https=) | ||
| JP2020055853A5 (https=) | ||
| JP2025065211A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2020503273A5 (https=) | ||
| JP2018532383A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| JPWO2020081497A5 (https=) | ||
| JPWO2021055350A5 (https=) | ||
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела |